Telesis Bio to Present at RNA Leaders Europe Congress
Telesis Bio Inc. (NASDAQ: TBIO) announced its participation at the RNA Leaders Europe Congress in Basel, Switzerland, on March 15, 2023, to showcase its benchtop automation solutions for mRNA synthesis. Presentations will include insights on optimizing CAR-T development workflows and addressing mRNA synthesis bottlenecks. The award-winning BioXp® system allows automated mRNA synthesis from sequence or plasmid DNA, enabling faster acquisition of mRNA in days instead of weeks. Dr. Todd R. Nelson, CEO, asserts that this technology is crucial for accelerating drug discovery, particularly in oncology and vaccine development.
- None.
- None.
Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions for mRNA synthesis at RNA Leaders Europe Congress which begins tomorrow in Basel, Switzerland. In addition to exhibition, Telesis Bio will present in two sessions; Jyotsna Venugopal, Ph.D., Director of Product Marketing, will present “Automated synthetic biology solutions for optimizing CAR-T development workflows” in the opening day session, and Qi Zhang, Ph.D., Scientist, will present “Automated solutions for addressing mRNA synthesis bottlenecks in therapeutics discovery” in the poster session.
The award winning BioXp® system and associated BioXp® mRNA synthesis kits enables on-demand and automated synthesis of mRNA beginning from a customer’s sequence or own plasmid DNA, overnight and at the push of a button. The system enables researchers to optimize their discovery workflows by acquiring their mRNA of interest in days, rather than weeks or months.
“By enabling researchers to overcome the bottleneck created by long lead times to build or buy their mRNA, they can more tightly integrate and more quickly execute their design-build-test workflows. We believe our BioXp® system can empower researchers to accelerate drug discovery, particularly in the areas of oncological and infectious disease vaccine discovery,” said Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio.
For more information on the BioXp® mRNA Synthesis Kits or to place an order, please visit telesisbio.com/products/bioxp-kits/mrna-synthesis/.
About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 11, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com
FAQ
What will Telesis Bio showcase at the RNA Leaders Europe Congress on March 15, 2023?
Who will present at the RNA Leaders Europe Congress for Telesis Bio?
What is the significance of the BioXp® system by Telesis Bio?
How does Telesis Bio's technology impact drug discovery?
What is the stock symbol for Telesis Bio?
